The target of R-etodolac has not been definitively established; the retinoid X receptor-α was identified as the target in prostate cancer and R-etodolac is associated with inhibition of the Wnt beta-catenin/TCF signaling pathways [116] in hematologic malignancies. The gene discussed is CTNNB1; the disease is Familial prostate cancer.